Ballicules › Drugs › Ergotamine
What it is Ergot alkaloid with 5-HT1B/1D and adrenergic agonism; acute migraine.
Why this one Long duration and low headache recurrence.
What limits it Peripheral and coronary vasospasm; contraindicated with CYP3A4 inhibitors and within 24 hours of a triptan. Medication-overuse headache develops readily.
FDA-approved for
FDA label
Read the full label on DailyMed ↗
BOXED WARNING Serious/life-threatening peripheral ischemia with coadministration of potent CYP3A4 inhibitors (protease inhibitors, macrolide antibiotics) — elevated ergotamine levels increase vasospasm risk (cerebral/extremity ischemia); concomitant use contraindicated.
FDA dosing Population Start Target Max
Acute migraine — abort or relieve attack adult 2 mg SL at first sign of attack 2 mg SL q30min PRN 6 mg (3 tablets)/24 h; 10 mg (5 tablets)/week
Renal Contraindicated in impaired renal function
Hepatic Contraindicated in impaired hepatic function
Patient-information section advises no more than 2 tablets per single attack (DOSAGE section allows 3/24 h); weekly max 5 tablets.
Instructions Place tablet under the tongue at first sign of attack — early administration gives maximum effectiveness Not for chronic daily administration Use only for migraine — not effective for other headache types; lacks analgesic properties Report numbness/tingling, limb muscle pain, leg weakness, chest pain, heart-rate changes, swelling or itching immediately
Contraindications Potent CYP3A4 inhibitors (ritonavir, nelfinavir, indinavir, erythromycin, clarithromycin, troleandomycin, ketoconazole, itraconazole) — acute ergotism with vasospasm/ischemia Pregnancy (women who are or may become pregnant) Peripheral vascular disease Coronary heart disease Hypertension Impaired hepatic or renal function Sepsis
Cautions Ergotism — intense arterial vasoconstriction and peripheral ischemia; can progress to gangrene; remain within recommended dosage Potential vasospasm risk even with less potent CYP3A4 inhibitors (saquinavir, nefazodone, fluconazole, fluoxetine, fluvoxamine, grapefruit juice, zileuton, metronidazole, clotrimazole) Fibrotic complications with long-term continuous use — retroperitoneal, pleuropulmonary, cardiac valve thickening Rebound headache (withdrawal) after long-term indiscriminate use
Adverse reactions Vasoconstrictive complications: ischemia, cyanosis, absent pulse, cold extremities, gangrene, precordial pain, EKG changes, muscle pain Transient tachycardia or bradycardia; hypertension Nausea and vomiting Paresthesias, numbness, weakness, vertigo Localized edema and itching
Pregnancy Category X — contraindicated; oxytocic effects (maximal 3rd trimester) and fetal growth retardation in animals.
Lactation Excreted in breast milk — may cause vomiting, diarrhea, weak pulse, unstable blood pressure in nursing infants; discontinue nursing or the drug.
⚠ BOXED WARNING
Serious vasospasm with CYP3A4 inhibitors
Cost, est. cash $500–$1,200/month
Generic entry 1982
Classes and tags
Clinical profile
Therapeutic safety burden 1 / 4
Overdose danger 1 / 4
Weight-gain liability 0 / 4
Sedation liability 0 / 4
QT / Torsades 0 / 4
Direct muscarinic antagonism 0 / 4
Embryofetal risk 1 / 4
Legacy pregnancy category Unknown / historical label unavailable
Defining liability Agent-specific vascular, serotonergic or hepatic risks; acute overdose is usually limited outside ergot or cardiovascular agents.
Mechanism of action: Ergotamine ballicule
Open Ergotamine in the interactive console ↗